Introduction
Anaerobes are frequent causes of human infections, especially in immunocompromised and otherwise debilitated hosts, e.g. intra-abdominal infections. β-Lactamase production is found in most of the Bacteroides fragilis group, and has increasingly been found in Prevotella, Porphyromonas and Fusobacterium spp. Clindamycin resistance is found in the B. fragilis group and some Clostridium strains, and metronidazole resistance, common among anaerobic Gram-positive non-spore-forming bacilli, has also been found in the B. fragilis group. [1] [2] [3] [4] The oxazolidinones are a new class of synthetic antimicrobial agent active mainly against Gram-positive organisms, including Gram-positive anaerobes such as Clostridium spp., Peptostreptococcus spp. and Propionibacterium acnes. Linezolid, the oxazolidinone for which most data are currently available, is active against staphylococci, streptococci, enterococci, aerobic Gram-positive non-spore-forming bacilli as well as some anaerobes. Activity against Gramnegative organisms is less marked. [5] [6] [7] [8] The current study examines the in vitro activity of AZD2563, a new oxazolidinone targeted at Gram-positive infections, 7 compared with that of linezolid, quinupristin/dalfopristin, amoxicillin, clindamycin, metronidazole, vancomycin, teicoplanin and meropenem against 300 Gram-positive and Gram-negative anaerobes. AZD2563 has a similar structure to linezolid, differing only at positions 3 and 4 of the aryl ring and on the C-5 side chain. 7
Materials and methods
Strains were all clinical isolates, most of which were isolated during the past 3 years and identified by conventional methodology. 9 Before testing, organisms were stored in double-strength skimmed milk (Difco Laboratories, Detroit, MI, USA) at -70°C. Purity throughout the study was checked by Gram's stain and colonial morphology. AZD2563 was obtained from AstraZeneca Laboratories (Macclesfield, Cheshire, UK) and other drugs from their respective manufacturers. Amoxicillin powder was obtained from Sigma Chemical Co., Inc. (St Louis, MO, USA). β-Lactamase production was tested by the cefinase disc method (BBL Microbiology Systems, Cockeysville, MD, USA). 1 Agar dilution MICs were determined according to NCCLS methodology using Brucella laked blood agar plates and inocula of 1 × 10 5 cfu/mL. 10 Plates were incubated for 48 h in anaerobic 
Results
MICs are presented in Table 1 Against Gram-negative bacilli, activity of both oxazolidinones, glycopeptides and quinupristin/dalfopristin was poor, especially against members of the B. fragilis group; oxazolidinone MICs were lower for Prevotella, Porphyromonas and Fusobacterium spp.
Although most strains were susceptible to clindamycin, resistance was encountered in some Gram-negative and Gram-positive strains, particularly Clostridium difficile. With the exception of anaerobic Gram-positive non-sporeforming bacilli, all anaerobes were susceptible to metronidazole. Meropenem was very active against all strains tested with the exception of two strains of lactobacilli (both also glycopeptide resistant), for which meropenem MICs were ≥8.0 mg/L.
Discussion
Goldstein and co-workers 5 have documented that the MIC of linezolid, the currently approved oxazolidinone, was ≤2.0 mg/L for fusobacteria, Prevotella spp., Porphyromonas spp. and peptostreptococci. Because only bite wound organisms were tested, no strains of the B. fragilis group were tested. Wise and co-workers 6 have reported linezolid MICs of ≤4.0 mg/L for B. fragilis, <2.0 mg/L for Clostridium perfringens and 8.0 mg/L for C. difficile. MICs of AZD2563 for anaerobes in the current study were similar to those described above for linezolid, with lower MICs for Gram-positive compared with Gram-negative organisms and also low MICs for fusobacteria. Our results for linezolid are also similar to those of other workers cited above. 5, 6 Teicoplanin, like vancomycin, was active only against Gram-positive organisms. 5 MICs of other compounds tested in the current study were similar to those reported by other workers, [1] [2] [3] [5] [6] [7] with meropenem having the greatest overall activity against all groups of bacteria. [1] [2] [3] In summary, both AZD2563 and linezolid were active against most Gram-positive anaerobes. These results provide a basis for testing the clinical performance of AZD2563 in skin and soft tissue infections caused by aerobic and anaerobic Gram-positive organisms.
